Observational studyThe oncologist2024

Prospective Observational Study of Ramucirumab Plus Docetaxel After Combined Chemoimmunotherapy in Patients With Non-Small-Cell Lung Cancer.

Yuki Katayama et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.